Related Experiment Video
Updated: May 24, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Calciphylaxis in CKD and beyond
Vincent M Brandenburg1, Rafael Kramann, Paula Specht
1Department of Cardiology, RWTH University Hospital, Aachen, Germany.
Insights
Calciphylaxis, a rare disease affecting dialysis patients, significantly reduces quality of life. Vitamin K antagonist use is a key risk factor, unlike hyperparathyroidism, highlighting areas for improved patient care.
Area of Science:
- Nephrology
- Dermatology
- Rare Diseases
Background:
- Calciphylaxis is a rare, severe condition primarily affecting patients on hemodialysis, leading to reduced quality of life and high mortality.
- The exact causes and risk factors, both local and systemic, for calciphylaxis remain incompletely understood.
- There are persistent uncertainties in the diagnosis and management of calciphylaxis, necessitating standardized approaches.
Purpose of the Study:
- To investigate the clinical and laboratory parameters associated with calciphylaxis development.
- To identify relative risks for various factors contributing to calciphylaxis.
- To address diagnostic and therapeutic uncertainties in calciphylaxis management.
Main Methods:
- A survey was conducted collecting data from calciphylaxis patients.
- Clinical and laboratory data were compared between calciphylaxis patients and control subjects.
- Relative risks for calciphylaxis development were calculated for various parameters.
Main Results:
- Vitamin K antagonist usage was identified as a significant risk factor for calciphylaxis.
- Uncontrolled hyperparathyroidism appeared to play a secondary role in calciphylaxis development.
- Survey and registry data offer insights into calciphylaxis etiology.
Conclusions:
- Vitamin K antagonist use is an important factor to consider in calciphylaxis.
- Further research using survey and registry data is crucial for improving calciphylaxis prevention and outcomes.
- Standardized diagnostic and treatment strategies are needed for calciphylaxis.
Abstract:
Calciphylaxis is still an incompletely understood rare disease, which most often affects people on haemodialysis. For the majority of patients, calciphylaxis means a massive reduction in quality of life and is associated with high morbidity and mortality. We still know little about the concert of local and systemic risk factors and underlying causes that finally lead to the development of calciphylaxis. Recent work from Asia points towards persistent uncertainties in the diagnosis and management of the disease which the nephrology community has to address by establishing standards in both diagnosis as well as treatment strategies. Hayashi et al. have published results from a Japanese survey in which the authors collected data from calciphylaxis patients and compared clinical and laboratory data with those of control subjects. This innovative approach allowed the authors to calculate relative risks for various parameters in terms of calciphylaxis development. While uncontrolled hyperparathyroidism seemingly plays a secondary role, vitamin K antagonist usage proved to be of particular importance. Survey as well as registry data may help to close the gap in our knowledge about calciphylaxis which may ultimately result in improved prevention, patient care and outcome.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease IV: Nursing Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Skeleton and Calcium Homeostasis

